GEHC vs SYK: Which Health Stocks Offer Better Value Right Now?

If you’re hunting for undervalued health stocks in the medical products sector, two companies likely crossed your radar: GE HealthCare Technologies (GEHC) and Stryker (SYK). Both are established players in medical equipment and technology, but which one actually presents a better opportunity for value-focused investors today?

Earnings Outlook Favors GE HealthCare

When evaluating investment potential, we combine two powerful tools: the Zacks Rank system and our Style Scores methodology. The Zacks Rank identifies companies with positive earnings estimate revision trends—essentially companies gaining momentum among analysts. Our Style Scores, meanwhile, grade stocks across multiple dimensions including value characteristics.

Currently, GEHC carries a Zacks Rank of #2 (Buy), while SYK holds a #3 (Hold). This ranking advantage suggests that GE HealthCare has seen stronger improvement in its earnings outlook compared to Stryker recently. For investors seeking health stocks positioned for growth, this distinction matters—it indicates which company’s fundamentals are strengthening in the eyes of the analyst community.

Valuation Metrics Tell a Clear Story

Beyond rankings, we examine traditional valuation metrics that reveal whether a stock trades at a discount. These metrics form the backbone of value investing and help separate genuinely undervalued opportunities from overpriced ones.

The forward P/E ratio comparison is striking: GEHC trades at a forward P/E of 15.89, while SYK sits at 24.22. A lower P/E typically signals better value—you’re paying less per dollar of expected earnings. This 8-point spread is substantial when comparing health stocks in the same sector.

The PEG ratio adds another dimension by factoring in growth rates. GEHC’s PEG of 1.75 suggests its valuation is aligned with its growth prospects, while SYK’s 2.11 indicates a pricier tag relative to its growth trajectory. When growth doesn’t justify the valuation premium, investors should take notice.

Perhaps most telling is the Price-to-Book (P/B) ratio. GEHC’s P/B of 3.47 represents a more reasonable relationship between market value and book value (total assets minus liabilities). SYK’s P/B of 6.16 is nearly double—a significant premium that raises questions about whether current market expectations are justified.

Key Financial Ratios Comparison

To provide perspective, here’s how these health stocks stack up across multiple dimensions:

GEHC receives a Value grade of A, reflecting its attractive positioning across these and other fundamental metrics. Stryker earns a C, suggesting less compelling value at current price levels.

Which Medical Stock Deserves Your Attention?

For investors specifically seeking undervalued health stocks, the data points decidedly toward GE HealthCare Technologies. It combines a stronger Zacks Rank trajectory with materially cheaper valuation multiples across nearly every traditional metric. Stryker remains a solid company, but its premium valuation appears less justified given current earnings expectations.

The research community continues to identify opportunities within medical products stocks, but GEHC’s combination of improving earnings estimates and attractive valuation metrics positions it as the more compelling value opportunity in this comparison. As always, individual investors should conduct their own due diligence, but these metrics suggest where the greater margin of safety lies for value-oriented portfolios.

Information sourced from Zacks Investment Research analysis. The views expressed represent analysis of publicly available financial data and do not constitute investment advice. Past performance, such as Hims & Hers Health’s historical gains, does not guarantee future results.